Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.
[BACKGROUND] Dacomitinib, a second-generation, irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), showed statistically significant progression-free survival improvement
- 표본수 (n) 261
- 95% CI 14.5-19.8
- 연구 설계 cohort study
APA
Wu L, Li J, et al. (2026). Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.. Lung cancer (Amsterdam, Netherlands), 211, 108856. https://doi.org/10.1016/j.lungcan.2025.108856
MLA
Wu L, et al.. "Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.." Lung cancer (Amsterdam, Netherlands), vol. 211, 2026, pp. 108856.
PMID
41365111
Abstract
[BACKGROUND] Dacomitinib, a second-generation, irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), showed statistically significant progression-free survival improvement over gefitinib in patients with treatment-naive EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in the phase 3 ARCHER 1050 study (NCT01774721). We report results from the final analysis of ARIA (NCT04609319), a noninterventional study of dacomitinib's real-world utilization and associated clinical outcomes in Asian patients with EGFR mutation-positive advanced NSCLC.
[METHODS] This longitudinal, multicenter cohort study collected prospective and retrospective data from patients with EGFR mutation-positive locally advanced or metastatic NSCLC who were treated with first-line dacomitinib. Study objectives were to describe clinical and disease characteristics, therapeutic patterns of dacomitinib use, and clinical outcomes.
[RESULTS] 299 patients located in China (n = 261), India (n = 24), and Malaysia (n = 14) were enrolled and included in the analysis. Starting dose was 30 mg once daily in 159 (53.2 %) patients, 45 mg once daily in 138 (46.2 %), and other doses in 2 (0.7 %). As of May 28, 2024, 95 patients (31.8 %) had dose reductions, 47 (15.7 %) had dose increases, 41 (13.7 %) had dose interruptions, and 223 (74.6 %) had permanently discontinued dacomitinib. Median duration of treatment was 17.2 months (IQR, 19.2). Median time to treatment failure was 17.0 months (95 % CI, 14.5-19.8). Median progression-free survival was 20.1 months (95 % CI, 17.4-22.4). 148 (49.5 %) patients had treatment-related adverse events; most common were rash (n = 93 [31.1 %]), diarrhea (n = 81 [27.1 %]), and paronychia (n = 57 [19.1 %]).
[CONCLUSIONS] To our knowledge, ARIA is the largest real-world study of dacomitinib's efficacy and safety. Final analysis of this study showed substantial clinical efficacy of dacomitinib and revealed treatment patterns, such as starting dose, in the real world. Safety data were consistent with dacomitinib's known safety profile. These results support first-line dacomitinib use in Asian patients with EGFR mutation-positive advanced NSCLC.
[CLINICALTRIALS] gov NCT04609319.
[METHODS] This longitudinal, multicenter cohort study collected prospective and retrospective data from patients with EGFR mutation-positive locally advanced or metastatic NSCLC who were treated with first-line dacomitinib. Study objectives were to describe clinical and disease characteristics, therapeutic patterns of dacomitinib use, and clinical outcomes.
[RESULTS] 299 patients located in China (n = 261), India (n = 24), and Malaysia (n = 14) were enrolled and included in the analysis. Starting dose was 30 mg once daily in 159 (53.2 %) patients, 45 mg once daily in 138 (46.2 %), and other doses in 2 (0.7 %). As of May 28, 2024, 95 patients (31.8 %) had dose reductions, 47 (15.7 %) had dose increases, 41 (13.7 %) had dose interruptions, and 223 (74.6 %) had permanently discontinued dacomitinib. Median duration of treatment was 17.2 months (IQR, 19.2). Median time to treatment failure was 17.0 months (95 % CI, 14.5-19.8). Median progression-free survival was 20.1 months (95 % CI, 17.4-22.4). 148 (49.5 %) patients had treatment-related adverse events; most common were rash (n = 93 [31.1 %]), diarrhea (n = 81 [27.1 %]), and paronychia (n = 57 [19.1 %]).
[CONCLUSIONS] To our knowledge, ARIA is the largest real-world study of dacomitinib's efficacy and safety. Final analysis of this study showed substantial clinical efficacy of dacomitinib and revealed treatment patterns, such as starting dose, in the real world. Safety data were consistent with dacomitinib's known safety profile. These results support first-line dacomitinib use in Asian patients with EGFR mutation-positive advanced NSCLC.
[CLINICALTRIALS] gov NCT04609319.
MeSH Terms
Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Longitudinal Studies; Lung Neoplasms; Mutation; Neoplasm Metastasis; Prospective Studies; Protein Kinase Inhibitors; Quinazolinones; Retrospective Studies; Treatment Outcome
같은 제1저자의 인용 많은 논문 (5)
- Introducing Saddle-Shaped Radix Graft, with a Second Look into the Classic.
- Phosphorylated DHX9 inhibited the progression of lung adenocarcinoma by regulating R-loops mediated DNA damage.
- Lycorine inhibits the proliferation of acute myeloid leukemia cells by upregulating the expression of THBS1.
- Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.
- Study on Dual-Targeted Liposomes Containing Curcumin-Copper Chelate in the Treatment of Triple-Negative Breast Cancer.